Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma

Objective: Increased visceral fat and sarcopenia are cardiovascular risk factors that may explain increased cardiovascular morbidity and frailty in patients with adrenal adenomas. Our objective was to compare body composition measurement of patients with adrenal adenomas to referent subjects without adrenal disease Design: Cross-sectional study, 2014-2018 Methods: Participants were adults with nonfunctioning adrenal tumor (NFAT), mild autonomous cortisol secretion (MACS) and Cushing syndrome (CS), and age, sex and body mass index 1:1 matched referent subjects without adrenal disorders. Main outcome measures were body composition measurements calculated from abdominal computed tomography imaging. Intraabdominal adipose tissue and muscle mass measurements were performed at the 3rd lumbar spine level. Results: Of 227 patients with adrenal adenomas, 20 were diagnosed with CS, 76 with MACS and 131 with NFAT. Median age was 56 years (range, 18-89), and 67% were women. When compared to referent subjects, patients with CS, MACS, and NFAT demonstrated a higher visceral fat (odds ratio (OR) of 2.2 [95% CI 0.9-6.5], 2.0 [1.3-3.2], and 1.8 [1.2-2.7] and a lower skeletal muscle area (OR of 0.01 [95% CI 0-0.09], 0.31 [0.18-0.49], and 0.3 [1.2-2.7]), respectively. For every 1 mcg/dL cortisol increase after overnight dexamethasone, visceral fat/muscle area ratio increased by 2.3 (P=0.02) and mean total skeletal muscle area decreased by 2.2cm2 (P=0.03). Conclusion: Patients with adrenal adenomas demonstrate a lower muscle mass and a higher proportion of visceral fat when compared to referent subjects, including patients with NFAT. Even a subtle abnormality in cortisol secretion may impact health of patients with adenomas.

Download Full-text

Correlation of skeletal muscle area and muscle attenuation between l3, c3, and t4 level in patients with cancer: results from the body-convert study group

Clinical Nutrition ESPEN ◽

10.1016/j.clnesp.2021.09.103 ◽

2021 ◽

Vol 46 ◽

pp. S576-S577

Author(s):

J. Van den Broeck ◽

M.J. Sealy ◽

C. Brussaard ◽

H. Jager-Wittenaar ◽

A. Scafoglieri

Keyword(s):

Skeletal Muscle ◽

The Body ◽

Study Group ◽

Muscle Area ◽

Patients With Cancer ◽

Muscle Attenuation ◽

Skeletal Muscle Area

Download Full-text

Early high protein intake and mortality in critically ill ICU patients with low skeletal muscle area and -density

Clinical Nutrition ◽

10.1016/j.clnu.2019.09.007 ◽

2020 ◽

Vol 39 (7) ◽

pp. 2192-2201 ◽

Cited By ~ 1

Author(s):

Wilhelmus G.P.M. Looijaard ◽

Ingeborg M. Dekker ◽

Albertus Beishuizen ◽

Armand R.J. Girbes ◽

Heleen M. Oudemans-van Straaten ◽

...

Keyword(s):

Skeletal Muscle ◽

Critically Ill ◽

Protein Intake ◽

High Protein ◽

Muscle Area ◽

Icu Patients ◽

High Protein Intake ◽

Skeletal Muscle Area

Download Full-text

USEFULNESS OF SKELETAL MUSCLE AREA DETECTED BY COMPUTED TOMOGRAPHY TO PREDICT MORTALITY IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT: A META-ANALYSIS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(19)31712-7 ◽

2019 ◽

Vol 73 (9) ◽

pp. 1105

Author(s):

Mohamad Soud ◽

Fares Alahdab ◽

Gavin Ho ◽

Marco Cejudo-Tejeda ◽

Kayode Kuku ◽

...

Keyword(s):

Computed Tomography ◽

Skeletal Muscle ◽

Aortic Valve ◽

Aortic Valve Replacement ◽

Valve Replacement ◽

Transcatheter Aortic Valve Replacement ◽

Meta Analysis ◽

Muscle Area ◽

Transcatheter Aortic Valve ◽

Skeletal Muscle Area

Download Full-text

Skeletal muscle area and density are associated with lipid and lipoprotein cholesterol levels: The Multi-Ethnic Study of Atherosclerosis

Journal of Clinical Lipidology ◽

10.1016/j.jacl.2020.01.002 ◽

2020 ◽

Vol 14 (1) ◽

pp. 143-153 ◽

Cited By ~ 2

Author(s):

Chantal A. Vella ◽

Megan C. Nelson ◽

Jonathan T. Unkart ◽

Iva Miljkovic ◽

Matthew A. Allison

Keyword(s):

Skeletal Muscle ◽

Lipoprotein Cholesterol ◽

Muscle Area ◽

Ethnic Study ◽

Cholesterol Levels ◽

Skeletal Muscle Area

Download Full-text

The relationship between dose to skeletal muscle area ratio and gemcitabine nab-paclitaxel toxicity in pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.4_suppl.492 ◽

2018 ◽

Vol 36 (4_suppl) ◽

pp. 492-492

Author(s):

Rachel Wong ◽

Julia Freckelton ◽

Daniel Croagh ◽

Darcy Quinn Holt ◽

Adrian Fox ◽

...

Keyword(s):

Skeletal Muscle ◽

Adverse Events ◽

Pancreatic Ductal Adenocarcinoma ◽

Surface Area ◽

Body Surface Area ◽

Body Surface ◽

Ductal Adenocarcinoma ◽

First Line ◽

Muscle Area ◽

Skeletal Muscle Area

492 Background: Combination gemcitabine and nab-paclitaxel (Gem-Nab-P) is a common regimen used to treat metastatic pancreatic ductal adenocarcinoma (PDAC). Toxicity is less than that associated with other combination metastatic regimens (FOLFIRINOX), but it is still associated with significant morbidity. Currently, Gem-Nab-P is dosed using estimated body surface area. This study investigates whether skeletal muscle assessment could be a useful tool in the dosing of Gem-Nab-P in metastatic PDAC. Methods: This study involved two sites and included patients who had received Gem-Nab-P between January 2013 and March 2017. A review of medical records was used to identify demographic, disease and first-cycle treatment information. Chemotherapy toxicity was defined as grade 3 or 4 adverse events using the National Cancer Institute Common Toxicity Criteria Adverse Events manual v4.0. Body composition analysis was performed on computed tomography scans at spinal level L3, using SliceOmatic software. SPSS software was used to for all statistical analysis, with a p value of < 0.05 considered significant. Results: We identified 52 patients treated with first-line Gem-Nab-P for PDAC. Median age was 65 years (57-73) and 24 (47%) were male. Median BMI at commencement of Gem-Nab-P was 24.7 kg/m2 (21.3-27.4) and 38 (58%) of the patients were myopenic before starting chemotherapy. Fourteen (27%) patients experienced toxicity during the first cycle of chemotherapy. Patients who experienced first-cycle chemotherapy-associated toxicity did not have a different median SkMA to those who did not (128.6 cm2 vs. 111.4 cm2, p= 0.2). There was also no difference in the gemcitabine dose to SkMA ratio (14.1 mg/cm2 vs. 14.4 mg/cm2, p=0.8), nab-paclitaxel to SkMA ratio (1.8 mg/cm2 vs. 1.8 mg/cm2, p=0.6) or combined dose equivalent to SkMA ratio (2.8 mg/cm2 vs. 2.9 mg/cm2, p=0.9) between the patients that experienced first cycle toxicity versus those that did not. Conclusions: This study suggests that a pancreatic cancer patient’s skeletal muscle area is unlikely to be a useful addition to conventional body surface area in the dosing of first line Gem-Nab-P, to reduce first-cycle toxicity.

Download Full-text